Leica Biosystems Expands Leading Digital Pathology Portfolio for the US with Multiple Launches at Pathology Visions 2025

VISTA, Calif., Oct. 1, 2025 /PRNewswire/ -- In a groundbreaking showcase of innovation designed to accelerate the digital transformation of pathology, Leica Biosystems proudly launches its latest, pioneering software solutions in the Aperio Digital Pathology portfolio at booth #313 during Pathology Visions.

Aperio HALO AP, an advanced AI-powered image management solution, developed in conjunction with Indica Labs, provides seamless integration of digital slides and data into an intuitive interface for rapid on-screen review with comprehensive workflows, live conferencing, and collaboration.

The Aperio AI Store, exclusively available via Aperio HALO AP, is a scalable analysis platform incorporating powerful analysis applications developed by an ever-expanding number of leading innovation partners, including Deep Bio, Histofy, Indica Labs, and Lunit, all seamlessly embedded in a single interface.

"Showcasing Aperio HALO AP and Aperio AI Store at Pathology Visions is not just a product launch but rather marks a major milestone in our goal of Transforming Pathology, Together," said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. "There are many partnerships and promises in the digital pathology world, which can be overwhelming for users to identify their right path forward. Building on our commitment to interoperability, we believe that providing broad access to AI analysis solutions through a single interface not only provides choice but also represents a practical solution to the growing challenge of multiple software systems and viewers."

"Delivering on our collaboration with Leica Biosystems, we are proud to bring forward the next wave of innovation in digital pathology software," said Steven Hashagen, CEO of Indica Labs. "As leaders in computational pathology, we are continually advancing the field, coupling deep expertise with sophisticated artificial intelligence. This technology has the potential to not only elevate diagnostic precision and speed but also pave the way for more personalized and effective patient care."

Pharmaceutical companies needing AI-powered diagnostics can partner with Leica Biosystems to build custom AI applications for the AI Store and accelerate development. Built for seamless integration within Aperio HALO AP, the Aperio AI Store delivers unmatched interoperability across an end-to-end computational pathology workflow. This open, flexible platform empowers partners to streamline development, scale algorithms, and deliver new AI applications that provide insights beyond the limits of human interpretation. These unique capabilities further enable the Leica Biosystems network of pharmaceutical partnerships, exemplified by the partnership announced in May with AstraZeneca (read more).

Visit us at booth #313 to experience Aperio HALO AP and Aperio AI Store, in addition to our other innovative solutions including:

• Aperio GT 450 – world-leading brightfield scanner with a comprehensive range of functionality, including manual scan functionality, enabling users to accurately capture faintly stained or small fragments of tissue
• Aperio GT 180 – scanner for high-speed, high-quality brightfield scanning
• Aperio iQC – software for AI-powered automated quality control to deliver consistent and standardized WSI QC
• Aperio FL 120 – combined brightfield, fluorescent and FISH scanner providing flexibility for researchers to capture high-quality WSIs of all sample types
• HALO Link – a study-centric IMS leveraged by organizations worldwide to manage their research
• In the USA, Aperio HALO AP is For Research Use Only. Not For Use In Diagnostic Procedures. Aperio HALO AP is CE IVDR-marked for in-vitro diagnostic use. Not all products shown may be available for use in your country.

About Leica Biosystems

Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company's mission of "Advancing Cancer Diagnostics, Improving Lives" is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary.

Media Contact: 
Matthew McCutcheon
matthew.mccutchen@leicabiosystems.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/leica-biosystems-expands-leading-digital-pathology-portfolio-for-the-us-with-multiple-launches-at-pathology-visions-2025-302572031.html

SOURCE Leica Biosystems